138 related articles for article (PubMed ID: 14713280)
1. Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men.
Ross RJ; Jabbar A; Jones TH; Roberts B; Dunkley K; Hall J; Long A; Levine H; Cullen DR
Eur J Endocrinol; 2004 Jan; 150(1):57-63. PubMed ID: 14713280
[TBL] [Abstract][Full Text] [Related]
2. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
Dinsmore WW; Wyllie MG
BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
[TBL] [Abstract][Full Text] [Related]
3. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.
Korbonits M; Slawik M; Cullen D; Ross RJ; Stalla G; Schneider H; Reincke M; Bouloux PM; Grossman AB
J Clin Endocrinol Metab; 2004 May; 89(5):2039-43. PubMed ID: 15126518
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
6. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
Dobs AS; Matsumoto AM; Wang C; Kipnes MS
Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340
[TBL] [Abstract][Full Text] [Related]
7. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
[TBL] [Abstract][Full Text] [Related]
8. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
9. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
[TBL] [Abstract][Full Text] [Related]
10. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
Dobs AS; Hoover DR; Chen MC; Allen R
J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
15. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.
Yin AY; Htun M; Swerdloff RS; Diaz-Arjonilla M; Dudley RE; Faulkner S; Bross R; Leung A; Baravarian S; Hull L; Longstreth JA; Kulback S; Flippo G; Wang C
J Androl; 2012; 33(2):190-201. PubMed ID: 21474786
[TBL] [Abstract][Full Text] [Related]
16. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
Stuenkel CA; Dudley RE; Yen SS
J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a single dose of buccal testosterone.
Kim S; Snipes W; Hodgen GD; Anderson F
Contraception; 1995 Nov; 52(5):313-6. PubMed ID: 8585889
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.
Lee A; Rubinow K; Clark RV; Caricofe RB; Bush MA; Zhi H; Roth MY; Page ST; Bremner WJ; Amory JK
J Androl; 2012; 33(3):420-6. PubMed ID: 21868746
[TBL] [Abstract][Full Text] [Related]
20. Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone.
Wasserman P; Segal-Maurer S; Rubin D
J Sex Med; 2008 Jan; 5(1):241-7. PubMed ID: 17961146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
